• Info
  • Significant Ownership

Significant Ownership of Paragon Therapeutics, Inc.

Signature - Title
/s/ Keri Lantz - Keri Lantz, Chief Financial Officer
Location
Philadelphia, PA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Paragon Therapeutics, Inc..

Notify me when Paragon Therapeutics, Inc. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Paragon Therapeutics, Inc.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GLTO Galecto, Inc. Common Stock, par value $0.00001 per share 7.5% $3,494,922 120,473 Paragon Therapeutics, Inc. 10 Nov 2025

Schedules 13D/G Reported by Paragon Therapeutics, Inc.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.